CVS Health (CVS) Given a $95.00 Price Target at Royal Bank of Canada

CVS Health (NYSE:CVS) received a $95.00 target price from research analysts at Royal Bank of Canada in a research report issued to clients and investors on Monday, December 4th. The firm currently has a “buy” rating on the pharmacy operator’s stock. Royal Bank of Canada’s target price suggests a potential upside of 31.03% from the stock’s previous close.

A number of other research analysts have also recently commented on the company. Robert W. Baird restated a “hold” rating and issued a $77.00 target price on shares of CVS Health in a research note on Friday, October 27th. Needham & Company LLC raised CVS Health from a “hold” rating to a “buy” rating and raised their price objective for the company from $69.02 to $79.00 in a research report on Friday, November 10th. Mizuho set a $90.00 price objective on CVS Health and gave the company a “buy” rating in a research report on Tuesday, October 24th. BidaskClub lowered CVS Health from a “hold” rating to a “sell” rating in a report on Friday, August 25th. Finally, Loop Capital initiated coverage on CVS Health in a report on Thursday, August 24th. They issued a “hold” rating and a $83.00 target price for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $86.35.

CVS Health (NYSE:CVS) traded down $0.55 during midday trading on Monday, reaching $72.50. The company’s stock had a trading volume of 4,757,087 shares, compared to its average volume of 10,814,337. CVS Health has a 1-year low of $66.45 and a 1-year high of $84.72. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. The stock has a market cap of $73,999.07, a PE ratio of 14.98, a P/E/G ratio of 1.37 and a beta of 0.89.

CVS Health (NYSE:CVS) last released its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 EPS for the quarter, beating the Zacks’ consensus estimate of $1.49 by $0.01. The company had revenue of $46.18 billion during the quarter, compared to analysts’ expectations of $46.17 billion. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.64 EPS. equities analysts forecast that CVS Health will post 5.9 EPS for the current year.

In other news, EVP Thomas M. Moriarty sold 20,547 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $81.17, for a total transaction of $1,667,799.99. Following the transaction, the executive vice president now owns 43,178 shares of the company’s stock, valued at $3,504,758.26. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Lisa Bisaccia sold 29,445 shares of the company’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total value of $2,208,375.00. Following the transaction, the executive vice president now directly owns 15,556 shares in the company, valued at approximately $1,166,700. The disclosure for this sale can be found here. 0.61% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Atlantic Trust Group LLC boosted its holdings in shares of CVS Health by 4.5% in the third quarter. Atlantic Trust Group LLC now owns 1,484,499 shares of the pharmacy operator’s stock valued at $120,719,000 after purchasing an additional 64,123 shares during the period. Parametric Portfolio Associates LLC boosted its holdings in shares of CVS Health by 8.9% in the third quarter. Parametric Portfolio Associates LLC now owns 4,208,978 shares of the pharmacy operator’s stock valued at $342,274,000 after purchasing an additional 343,543 shares during the period. AXA lifted its holdings in CVS Health by 14.8% during the third quarter. AXA now owns 681,252 shares of the pharmacy operator’s stock worth $55,399,000 after buying an additional 87,634 shares during the period. Shelton Capital Management lifted its holdings in CVS Health by 19.4% during the third quarter. Shelton Capital Management now owns 52,860 shares of the pharmacy operator’s stock worth $4,299,000 after buying an additional 8,574 shares during the period. Finally, Chicago Partners Investment Group LLC lifted its holdings in CVS Health by 204.9% during the third quarter. Chicago Partners Investment Group LLC now owns 10,667 shares of the pharmacy operator’s stock worth $867,000 after buying an additional 7,169 shares during the period. 81.63% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was published by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://weekherald.com/2017/12/30/royal-bank-of-canada-reiterates-95-00-price-target-for-cvs-health-cvs.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply